Get started
Work

188P Time until definitive deterioration (TUDD) in patient-reported outcomes (PROs) with ripretinib vs sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib who harbor KIT exon 11 + 17/18 mutations: Exploratory analysis from INTRIGUE

Year: 2026
Type: article
DOI: 10.1016/j.esmorc.2026.100394
Authors: J-Y. Blay, R.L. Jones, H. Gelderblom, S. George, M. von Mehren, J.R. Zalcberg, Y-K. Kang, A.R. Abdul Razak, J.C. Trent, S. Attia, A. Le Cesne, B. Harrow, M. Smith, Y. Yuan, M.G. Sharma, M.L. Sherman, M. Heinrich, S. Bauer
Institutions: Centre Léon Bérard, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Leiden University Medical Center, Dana-Farber Cancer Institute, Fox Chase Cancer Center, Temple University Health System, Alfred Health, Monash University, Asan Medical Center, University of Ulsan, Princess Margaret Cancer Centre, University of Miami Health System, Sylvester Comprehensive Cancer Center, Mayo Clinic, Mayo Clinic in Florida, Institut Gustave Roussy, Fondation Gustave Roussy, Deciphera Pharmaceuticals (United States), Oregon Health & Science University, Portland VA Medical Center, VA Portland Health Care System, OHSU Knight Cancer Institute, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University of Duisburg-Essen
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,170
OpenAlex ID: W7134262144
FWCI:
Cites:
Cited by:
Related to: